63,82 €
- 2013
- 2015
- 2016
- 2018
- 2020
- 2022
- 2024
- 2026
- 0
- 50
- 150
- 200
- 250
ERTRÄGE
Warnung: Die Dividende wurde um 73,5% gekürzt auf 0,45 € pro Aktie. Dies könnte eine strategische Entscheidung sein oder auf veränderte finanzielle Prioritäten hinweisen. Aktionäre sollten prüfen, ob dies ein isolierter Rückschlag oder ein Zeichen struktureller Probleme ist.
0,45 €
Jährliche Dividende
0,70 %
Rendite
-73,50 %
Dividenden-Wachstum
29,10 %
Ausschüttungsquote
UNTERNEHMEN
9,4 Mrd. $
Umsatz
1,52 %
Umsatz-Wachstum
2,7 Mrd. $
Nettogewinn
-
53,6 %
ROE -
28,2 %
ROS -
18,3 %
ROA -
43,1 %
GPM
2,9 Mrd. $
Operativer Cashflow
5,0 Mrd. $
Eigenkapital
13.800
Mitarbeiter
-
680.942,0 $
Umsatz / MA -
192.101,4 $
Gewinn / MA
KGV
24,02 $KBV
12,88 $KCV
28,46 $KUV
6,78 $EV/EBITDA
17,67 $EV/EBIT
20,22 $EV/FCF
31,91 $EV/Umsatz
7,61 $EnterpriseValue
71,5 Mrd. $Eigenkapitalrendite
53,56 %Umsatzrendite
28,21 %EBIT-Marge
37,63 %EBITDA-Marge
43,06 %Kapitalumschlag
0,65 $Gesamtkapitalrendite
18,29 %Eigenkapitalquote
0,34 $Fremdkapitalquote
0,66 $Verschuldungsgrad
1,93 $Dyn. Verschuldungsgrad
3,27 $Sachinvestitionsquote
-0,23 $Anlagendeckungsgrad 1
1,70 $Anlagendeckungsgrad 2
0,73 $Liquidität 1. Grades
0,60 $Liquidität 2. Grades
1,08 $Liquidität 3. Grades
2,04 $Dividende pro Aktie
1,73 $Dividendenrendite
1,21 %Ausschüttungsquote
29,10 %Buchwert pro Aktie
11,08 $Cashflow pro Aktie
6,52 $Stand: 30.09.2025 TTM
CEO
Kristin Peck
Kristin Peck, geboren am 12. Februar 1971 in New York City, ist seit dem 1. Januar 2020 Chief Executive Officer von Zoetis Inc. Sie hat einen Bachelor of Arts in Economics von der Georgetown University und einen MBA von der Columbia Business School. Peck trat 2010 in das Unternehmen ein. Ihr Vermögen wird auf 40 Millionen USD geschätzt. Peck besitzt Anteile an Zoetis.
Kristin Peck, geboren am 12. Februar 1971 in New York City, ist seit dem 1. Januar 2020 Chief Executive Officer von Zoetis Inc. Sie hat einen Bachelor of Arts in Economics von der Georgetown University und einen MBA von der Columbia Business School. Peck trat 2010 in das Unternehmen ein. Ihr Vermögen wird auf 40 Millionen USD geschätzt. Peck besitzt Anteile an Zoetis.
Fakten
-
Sitz
USA
-
Hauptsitz
Parsippany
-
Börsengang
01.02.2013
-
Ausstehende Aktien
446,95 Mio.
-
Mitarbeiter
13,80 Tsd.
-
Währung
USD
-
Sektor
Gesundheitswesen
-
Industrie
Drug Manufacturers - General
-
Börse
NYSE
-
Ticker
ZTS
-
Webseite
Aktie
Unternehmensinfos
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, refe...
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.